AN2 Therapeutics (ANTX) Return on Capital Employed (2022 - 2026)

AN2 Therapeutics (ANTX) has 5 years of Return on Capital Employed data on file, last reported at 53.68% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 53.68%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 53.68% (changed N/A YoY), and the FY2025 annual result was 55.8%, down 181.0% from the prior year.
• Return on Capital Employed advanced to 53.68% in Q1 2026 per ANTX's latest filing, from 68.21% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 28.03% in Q2 2022 and troughed at 72.0% in Q3 2024.
• A 5-year average of 52.59% and a median of 55.22% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed tumbled 3982 bps in 2023, then sank 112 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 42.65% in 2022, then retreated by 23 bps to 52.66% in 2023, then declined by 27 bps to 67.09% in 2024, then decreased by 2 bps to 68.21% in 2025, then grew by 21 bps to 53.68% in 2026.
• Business Quant data shows ANTX's Return on Capital Employed at 53.68% in Q1 2026, 68.21% in Q4 2025, and 67.09% in Q4 2024.